mine receptor–blocking drugs used in the tr eatment of symptoms such as nausea and gas-
troparesis (e.g., prochlorperazine, prometh azine, trimethobenzamide, thiethylperazine,
metoclopramide); and amoxapine, which is marketed as an antidepressant.
Neuroleptic-Induced Parkinsonism
Other Medication-Induced Parkinsonism
332.1 (G21.11) Neuroleptic-Induced Parkinsonism
332.1 (G21.19) Other Medication-Induced Parkinsonism
Parkinsonian tremor, muscular rigidity, akinesia (i.e., loss of movement or difficulty ini-
tiating movement), or bradykinesia (i.e., slowing movement) developing within a few
weeks of starting or raising the dosage of a me dication (e.g., a neuroleptic) or after reduc-
ing the dosage of a medication used  to treat extrapyramidal symptoms.
Neuroleptic Malignant Syndrome
333.92 (G21.0) Neuroleptic Malignant Syndrome
Although neuroleptic malignant syndrome is easily recognized in its classic full-blown
form, it is often heterogeneous in onset, pres entation, progression, and outcome. The clin-
ical features described below are those consid ered most important in making the diagno-
sis of neuroleptic malignant syndrome  based on consensus recommendations.